Revolution Medicines, Inc. has initiated Phase 1/1b trials for RMC-9805, a covalent, oral KRAS G12D inhibitor for RAS-dependent cancers and the first patient already dosed targeting KRAS G12D mutation-driven cancers.

This article summarized the latest R&D progress of Istradefylline, the Mechanism of Action for Istradefylline, and the drug target R&D trends for Istradefylline.

MDM2 is a crucial protein found in the human body that plays a significant role in regulating cell growth and division.

This article summarized the latest R&D progress of ADO-Trastuzumab Emtansine, the Mechanism of Action for ADO-Trastuzumab Emtansine, and the drug target R&D trends for ADO-Trastuzumab Emtansine.

Cerevance announced the start of their Phase 1 trial, with the first participant dosed to evaluate the safety, tolerability, and pharmacokinetics of CVN293.

This article summarized the latest R&D progress of Vadadustat, the Mechanism of Action for Vadadustat, and the drug target R&D trends for Vadadustat.

Mcl-1, also known as myeloid cell leukemia-1, is a protein that plays a crucial role in regulating cell survival and apoptosis (programmed cell death) in the human body.

This article summarized the latest R&D progress of Lymecycline, the Mechanism of Action for Lymecycline, and the drug target R&D trends for Lymecycline.

ImmPACT Bio USA, Inc has publicized that the initial patient has received treatment in the Phase 1/2 trial of IMPT-314.

This article summarized the latest R&D progress of Dydrogesterone, the Mechanism of Action for Dydrogesterone, and the drug target R&D trends for Dydrogesterone.

IL-17A, or Interleukin-17A, is a cytokine that plays a crucial role in the human body's immune response.

This article summarized the latest R&D progress of Ceftolozane, the Mechanism of Action for Ceftolozane, and the drug target R&D trends for Ceftolozane.